In­tel­liphar­ma­ceu­tics shares crushed as FDA ex­perts snub pain drug; Mon­cef Slaoui joins Mod­er­na board

→ Af­ter get­ting chas­tised by reg­u­la­tors in an in­ter­nal FDA re­view of Toron­to-based In­tel­liphar­ma­ceu­tics$IP­CI new pain drug Rex­ista, a pan­el of out­side ex­perts joined …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.